Based on the available evidence, FIT seems to be superior to FOBT screening, particularly in the detection of polyps. More study is warranted.
Compared with no screening, FIT-mid was associated with a cost per QALY of $4,350, which was robust to sensitivity analysis. If jurisdictions implement screening programs using FIT, volume-based contracts could be used to achieve lower prices for the FIT assays. To optimize FIT test performance, programs could include the testing of two to three stool samples.